YM BIOSCIENCES'S CANCER DRUG GETS APPROVAL IN INDIA

YM BioSciences Inc., a company engaged in the acquisition, development and commercialization of oncology and acute care products, has reported that India's Drug Controller General has granted marketing approval to nimotuzumab, an anti-EGFr monoclonal antibody, for the treatment of head & neck cancer.

BioSpectrum (http://www.biospectrumasia.com/content/210706IND1187.asp)